VX1

The VX1 system is designed to aid operators in the real-time annotation of atrial maps by identifying intra-cardiac electrograms that show spatiotemporal dispersion during atrial arrhythmias. It achieves this using a machine and deep learning algorithm, trained on an extensive electrogram database, to analyze signals from compatible catheters and provide visual cues, though its direct impact on guiding catheter ablation therapy is yet to be clinically established.

The VX1 system by Volta Medical is a software tool utilizing machine and deep learning algorithms to assist clinicians in real-time manual annotation of 3D anatomical and electrical maps of human atria. Its core function is to identify multipolar intra-cardiac atrial electrograms exhibiting spatiotemporal dispersion (termed Dispersed Electrograms or DEs) during atrial fibrillation or atrial tachycardia. The system analyzes electrogram data from compatible catheters and acquisition systems, presenting graphical cues to operators about DE locations and providing cycle length estimations. The algorithm was developed using a large database of electrogram snippets and operates as a standalone local application during procedures. Non-clinical evaluations showed strong correlation between VX1's DE identification and expert physician consensus, superior period estimation capabilities, and high accuracy (over 89%) in cross-validation. VX1 also outperformed electrophysiologists in time-limited annotation tasks. A clinical study involving 300 patients indicated VX1's implementation did not increase procedural risk or duration and demonstrated performance comparable to a predicate device's CFAE module in locating electrical signal transmission pattern disruptions. However, it is explicitly stated that the clinical significance of using VX1 to identify DEs for guiding catheter ablation of atrial arrhythmias has not been established by clinical investigations.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. What specific features of spatiotemporal dispersion does the VX1 algorithm prioritize for identification, and how does this differ from the general definition of Complex Fractionated Atrial Electrograms (CFAEs)?; Given the training on 1.5-second electrogram snippets, how does the VX1 system perform in identifying spatiotemporal dispersion patterns that evolve over longer durations during dynamic atrial fibrillation?; While the clinical significance for guiding ablation is not yet established, what are the potential intermediate clinical benefits or insights that VX1 provides to operators during an electrophysiology procedure?; How does the VX1's 'cycle length estimation' contribute to the identification of spatiotemporal dispersion, and is this estimation validated against other established methods in real-time clinical scenarios?; What are the key differences in the training dataset and discriminant algorithm conceptualization for the VX1 compared to the analytical parameters used by the predicate device's CFAE module?